Every Call of Duty since CoD4 has had some kind of Prestige system, where you reset your account for rewards you can show off to your teammates in the lobby. Prestige in Black Ops 7 follows a similar ...

LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that ...

LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at ...

(RTTNews) - ADC Therapeutics. (ADCT) is scheduled to host a conference call today at 8:00 a.m. EST to provide an update on its LOTIS-7 trial. LOTIS-7 is a Phase 1b open-label clinical trial evaluating ...

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA ...

ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta in combination with the bispecific antibody glofitamab ...

The MarketWatch News Department was not involved in the creation of this content. ZYNLONTA(R) in combination with glofitamab (COLUMVI(R)) demonstrated an 89.8% ORR and 77.6% CR across the 49 ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

Investing.com -- ADC Therapeutics SA (NYSE:ADCT) stock fell 22% Wednesday after the company released updated data from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with the ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...